CD137 agonist therapy can reprogram regulatory T cells into cytotoxic CD4+ T cells with antitumor activity

Journal of Immunology

Volumn 196, Issue 1, 2016, Pages 484-492

  Akhmetzyanova, Ilseyar ^a   Zelinskyy, Gennadiy ^a   Littwitz Salomon, Elisabeth ^a   Malyshkina, Anna ^a   Dietze, Kirsten K ^a   Streeck, Hendrik ^a   Brandau, Sven ^a   Dittmer, Ulf ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CD137 LIGAND; CD40 LIGAND; CYTOKINE; EOMES PROTEIN, MOUSE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; GRANZYME; GZMB PROTEIN, MOUSE; T BOX TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

AGONISTS; ANIMAL; BIOSYNTHESIS; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGY; IMMUNOTHERAPY; KNOCKOUT MOUSE; LYMPHOCYTE DEPLETION; METABOLISM; MOUSE; NEOPLASMS, EXPERIMENTAL; NUCLEAR REPROGRAMMING; REGULATORY T LYMPHOCYTE; TRANSPLANTATION; TUMOR CELL LINE;

4-1BB LIGAND; ANIMALS; ANTIGENS, CD137; CD40 LIGAND; CELL LINE, TUMOR; CELLULAR REPROGRAMMING; CYTOKINES; FORKHEAD TRANSCRIPTION FACTORS; GRANZYMES; IMMUNOTHERAPY; LYMPHOCYTE DEPLETION; MICE; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84953284516     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1403039     Document Type: Article

References (43)

1. Driessens, G., J. Kline, and T. F. Gajewski. 2009. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol. Rev. 229: 126-144.
2. Curran, M. A., W. Montalvo, H. Yagita, and J. P. Allison. 2010. PD-1 and CTLA- 4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. USA 107: 4275-4280.
3. Curran, M. A., M. Kim, W. Montalvo, A. Al-Shamkhani, and J. P. Allison. 2011. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 6: e19499.
4. Shuford, W. W., K. Klussman, D. D. Tritchler, D. T. Loo, J. Chalupny, A. W. Siadak, T. J. Brown, J. Emswiler, H. Ræcho, C. P. Larsen, et al. 1997. 4- 1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186: 47-55.
5. Kocak, E., K. Lute, X. Chang, K. F. May, Jr., K. R. Exten, H. Zhang, S. F. Abdessalam, A. M. Lehman, D. Jarjoura, P. Zheng, and Y. Liu. 2006. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res. 66: 7276-7284.
6. Curran, M. A., T. L. Geiger, W. Montalvo, M. Kim, S. L. Reiner, A. Al- Shamkhani, J. C. Sun, and J. P. Allison. 2013. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J. Exp. Med. 210: 743-755.
7. McHugh, R. S., M. J. Whitters, C. A. Piccirillo, D. A. Young, E. M. Shevach, M. Collins, and M. C. Byrne. 2002. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16: 311-323.
8. Robertson, S. J., R. J. Messer, A. B. Carmody, R. S. Mittler, C. Burlak, and K. J. Hasenkrug. 2008. CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells. J. Immunol. 180: 5267-5274.
9. Chen, W., H. Qin, B. Chesebro, and M. A. Cheever. 1996. Identification of a gagencoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J. Virol. 70: 7773-7782.
10. Iwashiro, M., T. Kondo, T. Shimizu, H. Yamagishi, K. Takahashi, Y. Matsubayashi, T. Masuda, A. Otaka, N. Fujii, A. Ishimoto, et al. 1993. Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells. J. Virol. 67: 4533-4542.
11. + regulatory T cells induced by chronic retroviral infection. Proc. Natl. Acad. Sci. USA 98: 9226-9230.
12. Udono, H., M. Mieno, H. Shiku, and E. Nakayama. 1989. The roles of CD8+ and CD4+ cells in tumor rejection. Jpn. J. Cancer Res. 80: 649-654.
13. Akhmetzyanova, I., G. Zelinskyy, S. Schimmer, S. Brandau, P. Altenhoff, T. Sparwasser, and U. Dittmer. 2013. Tumor-specific CD4+ T cells develop cytotoxic activity and eliminate virus-induced tumor cells in the absence of regulatory T cells. Cancer Immunol. Immunother. 62: 257-271.
14. Lahl, K., C. Loddenkemper, C. Drouin, J. Freyer, J. Arnason, G. Eberl, A. Hamann, H. Wagner, J. Huehn, and T. Sparwasser. 2007. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J. Exp. Med. 204: 57-63.
15. Glynn, J. P., J. L. McCoy, and A. Fefer. 1968. Cross-resistance to the transplantation of syngeneic Friend, Moloney, and Rauscher virus-induced tumors. Cancer Res. 28: 434-439.
16. Williams, R., D. W. Lee, B. D. Elzey, M. E. Anderson, B. S. Hostager, and J. H. Lee. 2009. Preclinical models of HPV+ and HPV- HNSCC in mice: an immune clearance of HPV+ HNSCC. Head Neck 31: 911-918.
17. Cobbold, S. P., and H. Waldmann. 1984. Therapeutic potential of monovalent monoclonal antibodies. Nature 308: 460-462.
18. Zelinskyy, G., K. K. Dietze, Y. P. Hüsecken, S. Schimmer, S. Nair, T. Werner, K. Gibbert, O. Kershaw, A. D. Gruber, T. Sparwasser, and U. Dittmer. 2009. The regulatory T-cell response during acute retroviral infection is locally defined and controls the magnitude and duration of the virus-specific cytotoxic T-cell response. Blood 114: 3199-3207.
19. Taraban, V. Y., T. F. Rowley, L. O'Brien, H. T. Chan, L. E. Haswell, M. H. Green, A. L. Tutt, M. J. Glennie, and A. Al-Shamkhani. 2002. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur. J. Immunol. 32: 3617-3627.
20. + regulatory T cell responses during Friend retrovirus infection. Eur. J. Immunol. 36: 2658-2670.
21. Barber, D. L., E. J. Wherry, and R. Ahmed. 2003. Cutting edge: rapid in vivo killing by memory CD8 T cells. J. Immunol. 171: 27-31.
22. + and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice. J. Immunol. 150: 4900-4910.
23. Schepers, K., M. Toebes, G. Sotthewes, F. A. Vyth-Dreese, T. A. Dellemijn, C. J. Melief, F. Ossendorp, and T. N. Schumacher. 2002. Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirusinduced sarcomas. J. Immunol. 169: 3191-3199.
24. Qui, H. Z., A. T. Hagymasi, S. Bandyopadhyay, M. C. St Rose, R. Ramanarasimhaiah, A. Ménoret, R. S. Mittler, S. M. Gordon, S. L. Reiner, A. T. Vella, and A. J. Adler. 2011. CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation. J. Immunol. 187: 3555-3564.
25. Bruder, D., M. Probst-Kepper, A. M. Westendorf, R. Geffers, S. Beissert, K. Loser, H. von Boehmer, J. Buer, and W. Hansen. 2004. Neuropilin-1: a surface marker of regulatory T cells. Eur. J. Immunol. 34: 623-630.
26. Melero, I., W. W. Shuford, S. A. Newby, A. Aruffo, J. A. Ledbetter, K. E. Hellström, R. S. Mittler, and L. Chen. 1997. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3: 682-685.
27. Vinay, D. S., and B. S. Kwon. 2012. Immunotherapy of cancer with 4-1BB. Mol. Cancer Ther. 11: 1062-1070.
28. Zippelius, A., P. Batard, V. Rubio-Godoy, G. Bioley, D. Liénard, F. Lejeune, D. Rimoldi, P. Guillaume, N. Meidenbauer, A. Mackensen, et al. 2004. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 64: 2865-2873.
29. Choi, B. K., J. S. Bæ, E. M. Choi, W. J. Kang, S. Sakaguchi, D. S. Vinay, and B. S. Kwon. 2004. 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells. J. Leukoc. Biol. 75: 785-791.
30. Elpek, K. G., E. S. Yolcu, D. D. Franke, C. Lacelle, R. H. Schabowsky, and H. Shirwan. 2007. Ex vivo expansion of CD4+CD25+Foxp3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J. Immunol. 179: 7295-7304.
31. Zheng, G., B. Wang, and A. Chen. 2004. The 4-1BB costimulation augments the proliferation of CD4+CD25+ regulatory T cells. J. Immunol. 173: 2428-2434.
32. da Silva Martins, M., and C. A. Piccirillo. 2012. Functional stability of Foxp3+ regulatory T cells. Trends Mol. Med. 18: 454-462.
33. Vendetti, S., T. S. Davidson, F. Veglia, A. Riccomi, D. R. Negri, R. Lindstedt, P. Pasquali, E. M. Shevach, and M. T. De Magistris. 2010. Polyclonal Treg cells enhance the activity of a mucosal adjuvant. Immunol. Cell Biol. 88: 698-706.
34. Addey, C., M. White, L. Dou, D. Coe, J. Dyson, and J. G. Chai. 2011. Functional plasticity of antigen-specific regulatory T cells in context of tumor. J. Immunol. 186: 4557-4564.
35. Vokær, B., N. Van Rompæy, P. H. Lemaître, F. Lhommé, C. Kubjak, F. S. Benghiat, Y. Iwakura, M. Petein, K. A. Field, M. Goldman, et al. 2010. Critical role of regulatory T cells in Th17-mediated minor antigen-disparate rejection. J. Immunol. 185: 3417-3425.
36. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483.
37. Sharma, M. D., D. Y. Hou, B. Baban, P. A. Koni, Y. He, P. R. Chandler, B. R. Blazar, A. L. Mellor, and D. H. Munn. 2010. Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8 (+) T cell priming in naive mice. Immunity 33: 942-954.
38. Sharma, M. D., L. Huang, J. H. Choi, E. J. Lee, J. M. Wilson, H. Lemos, F. Pan, B. R. Blazar, D. M. Pardoll, A. L. Mellor, et al. 2013. An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity 38: 998-1012.
39. Loebbermann, J., H. Thornton, L. Durant, T. Sparwasser, K. E. Webster, J. Sprent, F. J. Culley, C. Johansson, and P. J. Openshaw. 2012. Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection. Mucosal Immunol. 5: 161-172.
40. Choi, B. D., P. C. Gedeon, J. E. Herndon, II, G. E. Archer, E. A. Reap, L. Sanchez-Perez, D. A. Mitchell, D. D. Bigner, and J. H. Sampson. 2013. Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody. Cancer Immunol. Res. 1: 163.
41. + T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 105: 2845-2851.
42. Piconese, S., B. Valzasina, and M. P. Colombo. 2008. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J. Exp. Med. 205: 825-839.
43. Melero, I., S. Hervas-Stubbs, M. Glennie, D. M. Pardoll, and L. Chen. 2007. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 7: 95-106.